Crowdonomics
All companies
Akibah Health logo

Akibah Health

Operating

AkibaH Health Corp

Healthcare · San Jose, MI · Founded 2013

The world's first OtterBox-enabled, smartphone case glucometer!

Post-money valuation ⓘ
$6.0M
As of Apr 2020 · from Reg CF Offering (2019-12-11) · pre-money + amount raised, not a traded price
Total raised
$90,034
Crowd $73K · Private $18K · 3 rounds since 2017
Latest share price
$0.56
Reg CF · Common Stock · Dec 2019 offering price

Financials

FY2016–FY2019 · from SEC filings · hover any figure for its source
$0
−$75K
2016
$0
−$86K
2017
$0
−$18K
2018
$0
−$1K
2019
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2016 reviewed*
FY2017 reviewed
FY2018 reviewed
FY2019
Income statement
Revenue
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
Net income
-$75,261
-$86,418
-$18,385
-$1,279
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$0
$23,605
$117
$1,000
Accounts receivable
$0
$0
$0
$0
Total assets
$46,964
$40,701
$21,531
$24,324
Short-term debt
$11,219
$0
$165,768
$171,768
Long-term debt
$119,997
$115,663
$0
$0
Total liabilities
$131,216
$115,663
$165,768
$171,768
Other
Headcount
—
2
5
5

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$6.0M
pre-money
Reg CF · Common · Dec 2019

Blue bars are the pre-money valuation the company stated for a priced round.

Fundraising history

Raised $72.5K / $1.1MInvestors 107Post-money $6M
Reg CF · SAFE · Jan 2019Closedvia WeFunder
Raised $0 / $1.1M
Raised $17.5KInvestors 3

Team

4 people
Fathi AbdelsalamFounder
Founder and CEO

Fathi founded Akibah Health while finishing his graduate studies at Cornell University. The team committed itself to finding a way to improve the lives of people with diabetes after losing several of their loved ones to the condition and watching many others struggle with its complications. Prior to Akibah Health, he served as a senior patent examiner at the U.S. Patent and Trademark Office where he was immersed in the latest software and high-tech inventions pertaining to new ways of doing business (clients included Microsoft, IBM, Oracle, SAP, Accenture, et al.). He holds a Master of Public Administration degree with a focus on entrepreneurship and economic development, and dual Bachelor of Science degrees in industrial engineering and economics. He works full time with Akibah Health. As an entrepreneur-in-residence at TechTown, he gives other entrepreneurs advice and mentorship as needed. In his spare time, he loves to travel and learn about other peoples and cultures.

Haroon Latif
Head of Business Development, Part-time

Prior to joining Akibah Health, Haroon was a strategy consultant at L.E.K. Consulting in Boston, where he managed eleven commercial due diligence and strategy cases across various sectors, including retail, consumer, and healthcare. Haroon started his career at PricewaterhouseCoopers in London providing financial due diligence support to private equity firms. He has also worked with venture capital advisory firms in London and New York, helping multiple startups prepare for venture funding, and assisting numerous corporate clients in launching new ventures. Haroon has an MBA with Distinction from Cornell University and a master's in economics from the London School of Economics. He earned his BA in economics from the University of Manchester and is also a UK-qualified Chartered Accountant.

Larry Ellingson
Strategist

Larry Ellingson is the former Chairman of the American Diabetes Association. He retired from Eli Lilly and Company in 2001 after having been involved as a leader of global diabetes for Lilly for more than half of his career. He has held several other positions at Lilly including Director of Pharmaceutical New Product Planning for gastrointestinal, skeletal, endocrine, and infectious diseases. He was honored by being the first and only non–scientist to receive Eli Lilly’s President’s Award and the Lilly Research Award for contributions to diabetes research. Larry continues to remain active with committee work and board positions for a multitude of organizations. Among them are NDSU, Research Park, International Diabetes Federation, Academy of Nutrition and Dietetics, Nurse Practitioners Healthcare Foundation, and the ADA.

Paul Chang
Lead Engineer, Part-time

Paul received an M.Eng. in systems engineering and a B.S. in mechanical engineering from Cornell University. Prior to joining Akibah Health, he was the founder of Engineering World Health, a biomedical project team dedicated to developing low-cost medical devices. He is also the Co-Founder of the Cornell Rapid Prototyping Laboratory, where he provided 3D printing and rapid prototyping services for student projects. Additionally, he has developed solutions in several award-winning consumer product design projects, including Young Innovators in the Science, Play and Research Kit (SPARK) Competition. He has been involved with several organizations around the world, including MEDLIFE in Peru, Project Peanut Butter in Malawi, Okutoeru Consulting in Japan, and Giant Bicycle and TSMC in Taiwan.

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 1 of 8 annual reports (FY2018–FY2025)

107 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-TRApr 6, 20210001665160-21-000421
    EDGAR
  • Form C-ARJun 4, 20200001665160-20-000705
    EDGAR
  • Form C-UMay 5, 20200001665160-20-000566
    EDGAR
  • Form C/AMar 10, 20200001665160-20-000209
    EDGAR
  • Form CDec 11, 20190001665160-19-001181
    EDGAR
  • Form CJan 14, 20190001670254-19-000004
    EDGAR
  • Form DMar 23, 20170001701666-17-000001
    EDGAR
Source: ManualCIK 0001701666DEShare price $0.56

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.